Staging Endometrial caNcer Based on molEcular ClAssification
NCT05707312 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1032
Last updated 2023-01-31
Summary
The SENECA study tries to evaluate the rate of lymph node involvement depending on the molecular subgroup in early-stage endometrial cancer (I/II) patients undergoing surgery as part of their treatment.
Conditions
- Endometrial Cancer
- Lymph Node Metastasis
- Sentinel Lymph Node
Sponsors & Collaborators
-
Clinica Universidad de Navarra, Universidad de Navarra
lead OTHER
Principal Investigators
-
Luis Chiva, MD PHD · Clinica Universidad de Navarra
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-01-01
- Primary Completion
- 2023-09-30
- Completion
- 2023-12-31
Countries
- Spain
Study Locations
More Related Trials
-
Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors
NCT01215578 ·Status: TERMINATED ·Phase: PHASE2
-
Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients
NCT05701241 ·Status: RECRUITING ·Phase: PHASE4
-
MEtatastic Renal Carcinoma LINes
NCT03928964 ·Status: UNKNOWN
-
Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response
NCT00694096 ·Status: COMPLETED ·Phase: PHASE1
-
REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
NCT03916458 ·Status: COMPLETED
-
Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma
NCT02689167 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
NCT01731925 ·Status: UNKNOWN ·Phase: PHASE2
-
Bintrafusp Alfa Program Rollover Study
NCT05061823 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating Renal Cell Carcinoma Risk Factors
NCT00927043 ·Status: COMPLETED
-
Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib
NCT02019576 ·Status: COMPLETED ·Phase: PHASE2
-
Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer
NCT00555672 ·Status: COMPLETED ·Phase: PHASE1
-
Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib
NCT03129724 ·Status: UNKNOWN
-
Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies
NCT01058707 ·Status: COMPLETED ·Phase: PHASE1
-
Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy
NCT02282579 ·Status: COMPLETED
-
Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy
NCT00663559 ·Status: COMPLETED ·Phase: PHASE2
-
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
NCT00814021 ·Status: COMPLETED ·Phase: PHASE2
-
Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer
NCT00059813 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases
NCT01444807 ·Status: UNKNOWN ·Phase: PHASE2
-
Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
NCT00537056 ·Status: COMPLETED ·Phase: NA
-
Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
NCT00378911 ·Status: COMPLETED ·Phase: PHASE2
-
Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A4061012
NCT01056263 ·Status: COMPLETED
-
A Phase II Study of AS1411 in Renal Cell Carcinoma
NCT00740441 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.
NCT05745142 ·Status: COMPLETED
-
Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib
NCT02713763 ·Status: COMPLETED ·Phase: PHASE2
-
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
NCT00474994 ·Status: COMPLETED ·Phase: PHASE2